Press Releases Synaptogenix, Inc.

Equities

SNPX

US87167T3005

Market Closed - Nasdaq Other stock markets 03:29:38 2024-05-20 pm EDT			5-day change	1st Jan Change
4.84 ^USD	+1.89%		+7.08%	-28.80%

Apr. 09	Synaptogenix, Inc. acquired Unknown Stake in Psyga Bio Ltd from Cannasoul Analytics Ltd.	CI
Apr. 03	Synaptogenix Plans 1-for-25 Reverse Stock Split; Shares Fall	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery	May. 07	PR
Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing	Apr. 24	PR
Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics	Apr. 09	PR
Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing	Apr. 03	PR
Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders	Dec. 19	PR
Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's	Dec. 06	PR
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by the Technion, Israel Institute of Technology	Nov. 03	AQ
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology	Nov. 02	PR
Niemann-Pick-Disease Pipeline, FDA Approvals, Clinical Trials, and Emerging Drugs 2023 (Updated)	23-09-28	AQ
Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease	23-09-26	PR
Synaptogenix : Certificate of Incorporation/Bylaws - Form 8-K	23-09-21	PU
Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study	23-09-07	PR
Synaptogenix and Cleveland Clinic to Submit Investigational New Drug Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis	23-07-20	AQ
Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis	23-07-19	PR
Stocks Set to Soar on News (EPAZ, BOPO, MBRX, SNPX)	23-07-14	AQ
Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience	23-07-13	PR
SYNAPTOGENIX, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	23-04-28	AQ
SYNAPTOGENIX, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	23-04-14	AQ
SYNAPTOGENIX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-21	AQ
Synaptogenix : Results of Operations and Financial Condition - Form 8-K	23-03-07	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Synaptogenix, Inc.

Equities

SNPX

US87167T3005

Press Releases

Filters